United Kingdom · Telehealth platform · Brand-name
Voy review
The full UK brand-name range including Foundayo, each listed with a headline weight-loss percentage — and no prices at all.
Overview
Voy lists the widest brand-name range we found in the UK: Mounjaro, Wegovy injection, the Wegovy pill, Foundayo and orlistat, each tagged with a headline figure — “up to 23% body weight loss” for Mounjaro, 21% for Wegovy, 17% for the Wegovy pill, 12% for Foundayo and 8% for orlistat.
Those percentages are marketing shorthand for trial results, and “up to” is doing real work in them. The controlled-trial averages behind these molecules are lower: 20.9% for tirzepatide at 72 weeks and 14.9% for semaglutide at 68 weeks. A ceiling figure is not an expected outcome.
Support is described as “access to our team of clinicians” with “human support via our app, phone or email.” No pricing appears anywhere on the page, and neither do plan lengths, membership fees, BMI criteria, shipping terms or cancellation policy.
Medications and supply
Brand-name. Mounjaro carries a UK weight-management licence, unlike the US brand.
- Mounjaro (tirzepatide)
- Wegovy (semaglutide) injection
- Wegovy pill (semaglutide)
- Foundayo (orforglipron)
- Orlistat / Orlos
How the service works
- Consultation
- Access to a team of clinicians, with support by app, phone or email.
- Eligibility
- Not stated. No BMI criteria are published.
- Provider involvement
- A clinician team with human support by app, phone or email.
- Lab requirements
- Not stated in the sources we checked.
- Pharmacy fulfilment
- Not stated in the sources we checked.
- Shipping
- Not stated in the sources we checked.
- Support services
- Human support via app, phone or email.
What it costs
| Item | Published price | Notes |
|---|---|---|
| All medications | not published | — |
- Membership fee
- Not stated in the sources we checked.
- Medication fee
- Not published.
- Insurance
- Not stated in the sources we checked.
- HSA / FSA
- Not stated in the sources we checked.
- Cancellation
- Not stated in the sources we checked.
- Refunds
- Not stated in the sources we checked.
Pros
- The widest brand-name range we found in the UK, including Foundayo
- Human support by phone and email as well as app
Cons
- No pricing published anywhere
- Headline percentages are “up to” ceilings, not expected averages
- Nothing published on eligibility, plan lengths, shipping or cancellation
Who it may suit
A UK buyer wanting the widest brand choice, who will get a price list before committing.
Limitations
- UK market only
- The published percentages are best-case figures rather than trial averages
Questions
Is Mounjaro really “up to 23%”?
That is a ceiling, not an average. The SURMOUNT-1 trial average for tirzepatide 15 mg was 20.9% at 72 weeks, and individual response varies widely. Read “up to” as the best case.
Sources
Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.
- 01Voy — medication range and headline efficacy claims, support modelretrieved 2026-08-15